President Donald Trump speaks speaks on the latest developments of the coronavirus outbreak, while flanked by White House coronavirus response coordinator Debbie Birx (L), and U.S. Surgeon General Jerome Adams (R), in the James Brady Press Briefing Room at the White House March 19, 2020. (Photo by Chip Somodevilla/Getty Images)
President Donald Trump in a press conference on Thursday said the Food and Drug Administration is fast-tracking efforts to approve an antiviral therapy, best known for treating malaria, for use in coronavirus cases.
The drug, hydroxychloroquine, was developed more than a half-century ago and is approved for treating malaria, arthritis, and other ailments. Reports out of China and Italy suggest the drug may help, but there is no hard data yet.
"We're going to be able to make that drug available almost immediately," Trump said.
The FDA is working to conduct a "large, pragmatic clinical trial" quickly to confirm the drug's benefit to coronavirus patients, said Commissioner Dr. Stephen Hahn.
He also tempered the president's optimism about the still-untested solution.
"What's also important is not to provide false hope," he said. "We may have the right drug, but it might not be in the appropriate dosage form right now, and it might do more harm than good."
New antiviral therapies face a shorter and less arduous approval process than vaccines, several of which are under development with 12 to 18-month timelines.
"The therapies are something we could move on much faster potentially," Trump said.
He claimed the administration "slashed red tape" to develop new vaccines and therapies.
The president also held out on confirming whether he would invoke the Defense Production Act, which he signed on Wednesday, to mandate the production of needed medical supplies such as N95 respirators and surgical masks.
"If we find that we need something, then we will do that," he said.
Trump repeated that he was open to the federal government buying equity stakes in the airline, cruise, hospitality, and other industries hurt by the outbreak.
The press conference opened with more controversial language placing the blame squarely on China for the outbreak, despite concerns voiced about potentially exacerbating a backlash against Asian Americans.
"We continue our relentless effort to defeat the Chinese virus," Trump said.
Epidemiologist Dr. Eric Feigl-Ding joined Closing Bell to explain why ending the travel mask mandates could put the U.S. in a bad position in the coming months as new COVID-19 variants threaten to cause another spike in cases.
Toby Fricker, the chief of communications for UNICEF, joined Cheddar News to discuss the humanitarian crisis in Ukraine as the Russian invasion continues, displacing at least five million refugees from their home country. "The situation for children is horrific when you have to leave your home. I mean, that's traumatic for any child anywhere, but being forced to run for your life literally is really horrific to think about that," he said.
Laurence Tribe, a professor of constitutional law at Harvard University, joined Cheddar News to talk about the legal underpinnings of the ruling to lift the federal travel mask mandate. "Judge Mizelle decided that she would issue a nationwide injunction, which she and other conservatives have criticized in the past," he said. "That didn't stop her from doing it this time. She did it by just wiping away the CDC's rule, and she did it, have to say, in an opinion that was, well, I'll be honest, really stupid."
Marijuana legalization has spread across the country in recent years, and the number of Americans in support of legalization is at an all-time high. Andrew Bowden, CEO of the premium cannabis brand Item 9 Labs, joined Cheddar to break down the inner workings of the industry and how the industry can grow from here.
After a nationwide mask mandate for travel was struck down by a federal judge, Dr. Sampson Davis, an ER physician and bestselling author, joined Cheddar News to talk about the ramifications. "We are at a place where we are going to have to wait and see, unfortunately," he said. "The good news is that we're coming off a celebration of spring break, Easter, Passover, and we'll see what happens. But right now I'm not seeing a spike and people come into the hospital are truly sick. However, I'm still seeing people test positive for COVID."
Chris Vecchio, senior strategist at DailyFX, says the James Bullard and the Fed's bark may be louder than its bite when it comes to potential rate hikes in May. Investors brushed off any causes for concerns during Tuesday's session, which led to stocks ending the day sharply higher.
Catching you up on what you need to know on April 19, 2022, with a federal judge voiding mask mandates on public transportation, updates from the Russia and Ukraine war, Mac Miller’s drug dealer sentenced for involvement in the rapper's death, and more.
